ERLONAT IP 100 MG 30 s BT BOTTLE

ERLONAT IP 100 MG 30 s BT BOTTLE Specification

Salt Composition
Erlotinib 100 mg

Dosage Form
Solid / Oral Tablet

Life Span
24 Months from manufacturing date

Origin of Medicine
India

Pacakaging (Quantity Per Box)
1 Bottle of 30 tablets

Brand Name
Erlonat

Indication
Non-small cell lung cancer and metastatic pancreatic cancer

Packaging Type
Plastic Bottle

Drug Type
Prescription Drug

Ingredients
Erlotinib Hydrochloride

Physical Form
Tablet

Function
Anti-cancer medication, EGFR Tyrosine Kinase Inhibitor

Recommended For
Treatment of Non-Small Cell Lung Cancer (NSCLC) and Pancreatic Cancer

Dosage
As directed by the physician

Dosage Guidelines
Take one tablet daily or as prescribed

Suitable For
Adults

Quantity
30 Tablets

Storage Instructions
Store below 30C, protect from moisture and light

Hsn Code
30049099

Side Effects
Rash, diarrhea, loss of appetite, fatigue

Registration Status
Approved in various countries

Administration Route
Oral

Warning
Use under medical supervision

Shape
Round, film-coated

Contraindications
Hypersensitivity to Erlotinib or any component of the formulation

Strength
100 mg per tablet

Marketed By
Natco Pharma Ltd.

Color
White to off-white

Prescription Required
Yes

ERLONAT IP 100 MG 30 s BT BOTTLE Trade Information

Minimum Order Quantity
1 Bottle

Supply Ability
5000 Bottles Per Month

Delivery Time
2-10 Days

About ERLONAT IP 100 MG 30 s BT BOTTLE

ERLONAT IP 100 MG 30 s BT BOTTLE stands as a hot-selling, scarce therapy curated for those seeking enlightened solutions against Non-Small Cell Lung Cancer and metastatic pancreatic cancer. Each flawless, round, white to off-white film-coated tablet unlocks the superlative efficacy of Erlotinib Hydrochloride, a potent EGFR Tyrosine Kinase Inhibitor. Marketed by Natco Pharma Ltd. and approved globally, this prescription drug demands careful use under medical supervision. Its superior composition supports adult patients via oral administration, offering reliability through stringent manufacturing and robust packaging standards.

Unlocking Cancer Care: Targeted Use & Advantages

ERLONAT IP 100 MG 30 s BT BOTTLE is specifically used as an anti-cancer medication, offering a strong advantage in the treatment of Non-Small Cell Lung Cancer (NSCLC) and metastatic pancreatic cancer. Recommended for adults, this prescription-only therapy ensures optimized outcomes under physician guidance. It is used as a daily oral dose, empowering patients through precision-targeted therapy and contributing to improved prognosis and quality of life.

Certifications, Export Markets & Sample Policy: Efficient Logistics Assured

ERLONAT IP 100 MG 30 s BT BOTTLE receives approval in various countries and is supported by robust distribution certifications. Serving main export markets like India and beyond, its supply is managed with seamless logistics and reliable transport services to ensure timely delivery. The sample policy is typically tailored for verified traders, wholesalers, and exporters, maintaining quality across each shipment while meeting international demands efficiently and securely.

FAQ's of ERLONAT IP 100 MG 30 s BT BOTTLE:

Q: How should ERLONAT IP 100 MG be administered for maximum benefit?

A: ERLONAT IP 100 MG should be taken orally, typically once daily or as directed by a physician. Adhering to the prescription ensures optimal therapeutic effect and helps manage potential side effects.

Q: What is the primary usage of ERLONAT IP 100 MG 30 s BT BOTTLE?

A: This medication is primarily used to treat adults diagnosed with Non-Small Cell Lung Cancer (NSCLC) and metastatic pancreatic cancer by inhibiting EGFR activity to slow cancer progression.

Q: When can patients expect to see results from ERLONAT IP 100 MG?

A: Individual responses vary, but most patients may observe therapeutic effects after several weeks of consistent intake. It is vital to follow the physician's prescribed regimen for best results.

Q: Where is ERLONAT IP 100 MG 30 s BT BOTTLE manufactured and marketed?

A: ERLONAT IP 100 MG is manufactured in India by Natco Pharma Ltd. and is approved for use in various countries, ensuring global availability and quality.

Q: What process should be followed if a dose is missed or side effects occur?

A: If a dose is missed, consult your healthcare provider before taking the next tablet. For any adverse effects like rash or diarrhea, seek prompt medical advice for appropriate management and continued safety.

Tell us about your requirement